Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Deleted in azoospermia protein 2 (DAZ2) is a member of the DAZ gene family located on the Y chromosome, specifically in the AZFc region. It encodes an RNA-binding protein critical for spermatogenesis and is expressed exclusively in premeiotic germ cells such as spermatogonia. DAZ2 is structurally characterized by containing RNA recognition motif (RRM) domains and DAZ-repeats, with variation in repeat number and sequence. Deletions of DAZ2—commonly occurring in tandem with DAZ1—are highly associated with impaired spermatogenesis, oligozoospermia, and azoospermia, particularly in specific populations. DAZ2 is not a therapeutic target (such as a receptor or enzyme), but its deletion serves as a recognized biomarker for certain types of male infertility. There are no known drugs that directly target DAZ2, and it is not implicated in broader disease categories beyond male infertility related to its absence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Deleted in azoospermia protein 2 (DAZ2).